FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233236543> ?p ?o ?g. }

• W4233236543 abstract "Abstract Background The peak of the global COVID-19 pandemic has not yet been reached and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in which the host thrombotic and inflammatory responses seems to drive complications. Severe COVID-19 disease is linked to high mortality, hyperinflammation, and a remarkably high incidence of thrombotic events. We hypothesize a crucial pathophysiological role for the contact pathway of coagulation and the kallikrein-bradykinin pathway. Therefore, drugs that modulate this excessive thromboinflammatory response should be investigated in severe COVID-19. Methods In this adaptive, open-label multicenter randomized clinical trial we compare low molecular weight heparins at 50 IU anti-Xa/kg twice daily - or 75 IU anti-Xa twice daily for intensive care (ICU) patients - in combination with aprotinin to standard thromboprophylaxis in hospitalized COVID-19 patients. In the case of hyperinflammation, the interleukin-1-receptor antagonist anakinra will be added on top of the drugs in the interventional arm. In a pilot phase, the effect of the intervention on thrombotic markers (D-dimer) will be assessed. In the full trial, the primary outcome is defined as the effect of the interventional drugs on clinical status as defined by the WHO ordinal scale for clinical improvement. Discussion In this trial we target the thromboinflammatory response at multiple levels. We intensify the dose of low molecular weight heparins to reduce thrombotic complications. Aprotinin is a potent kallikrein pathway inhibitor that reduces fibrinolysis, activation of the contact pathway of coagulation, and local inflammatory response. Additionally, aprotinin has shown in vitro inhibitory effects on SARS-CoV-2 cellular entry. Because the excessive thromboinflammatory response is one of the most adverse prognostic factors in COVID-19, we will add anakinra, a recombinant interleukin-1 receptor antagonist, to the regimen in case of severely increased inflammatory parameters. This way, we hope to modulate the systemic response to SARS-CoV-2 and avoid disease progressions with a potentially fatal outcome. Trial registration This trial is registered in the EU Clinical Trials Register. Registration number: 2020-001739-28. Registered on 2020-04-10." @default.
• W4233236543 created "2022-05-12" @default.
• W4233236543 creator A5004694001 @default.
• W4233236543 creator A5005171481 @default.
• W4233236543 creator A5006394234 @default.
• W4233236543 creator A5007984532 @default.
• W4233236543 creator A5008432179 @default.
• W4233236543 creator A5012712033 @default.
• W4233236543 creator A5025928709 @default.
• W4233236543 creator A5032838343 @default.
• W4233236543 creator A5034862797 @default.
• W4233236543 creator A5040583442 @default.
• W4233236543 creator A5040625301 @default.
• W4233236543 creator A5040894632 @default.
• W4233236543 creator A5047905695 @default.
• W4233236543 creator A5055321140 @default.
• W4233236543 creator A5057802451 @default.
• W4233236543 creator A5058451521 @default.
• W4233236543 creator A5064393231 @default.
• W4233236543 creator A5064898626 @default.
• W4233236543 creator A5070978420 @default.
• W4233236543 creator A5072840972 @default.
• W4233236543 creator A5074148903 @default.
• W4233236543 creator A5078680614 @default.
• W4233236543 creator A5087980813 @default.
• W4233236543 date "2020-11-05" @default.
• W4233236543 modified "2023-09-27" @default.
• W4233236543 title "A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study" @default.
• W4233236543 doi "https://doi.org/10.21203/rs.3.rs-45711/v2" @default.
• W4233236543 hasPublicationYear "2020" @default.
• W4233236543 type Work @default.
• W4233236543 citedByCount "0" @default.
• W4233236543 crossrefType "posted-content" @default.
• W4233236543 hasAuthorship W4233236543A5004694001 @default.
• W4233236543 hasAuthorship W4233236543A5005171481 @default.
• W4233236543 hasAuthorship W4233236543A5006394234 @default.
• W4233236543 hasAuthorship W4233236543A5007984532 @default.
• W4233236543 hasAuthorship W4233236543A5008432179 @default.
• W4233236543 hasAuthorship W4233236543A5012712033 @default.
• W4233236543 hasAuthorship W4233236543A5025928709 @default.
• W4233236543 hasAuthorship W4233236543A5032838343 @default.
• W4233236543 hasAuthorship W4233236543A5034862797 @default.
• W4233236543 hasAuthorship W4233236543A5040583442 @default.
• W4233236543 hasAuthorship W4233236543A5040625301 @default.
• W4233236543 hasAuthorship W4233236543A5040894632 @default.
• W4233236543 hasAuthorship W4233236543A5047905695 @default.
• W4233236543 hasAuthorship W4233236543A5055321140 @default.
• W4233236543 hasAuthorship W4233236543A5057802451 @default.
• W4233236543 hasAuthorship W4233236543A5058451521 @default.
• W4233236543 hasAuthorship W4233236543A5064393231 @default.
• W4233236543 hasAuthorship W4233236543A5064898626 @default.
• W4233236543 hasAuthorship W4233236543A5070978420 @default.
• W4233236543 hasAuthorship W4233236543A5072840972 @default.
• W4233236543 hasAuthorship W4233236543A5074148903 @default.
• W4233236543 hasAuthorship W4233236543A5078680614 @default.
• W4233236543 hasAuthorship W4233236543A5087980813 @default.
• W4233236543 hasBestOaLocation W42332365431 @default.
• W4233236543 hasConcept C126322002 @default.
• W4233236543 hasConcept C168563851 @default.
• W4233236543 hasConcept C177713679 @default.
• W4233236543 hasConcept C2779134260 @default.
• W4233236543 hasConcept C2781228260 @default.
• W4233236543 hasConcept C535046627 @default.
• W4233236543 hasConcept C71924100 @default.
• W4233236543 hasConceptScore W4233236543C126322002 @default.
• W4233236543 hasConceptScore W4233236543C168563851 @default.
• W4233236543 hasConceptScore W4233236543C177713679 @default.
• W4233236543 hasConceptScore W4233236543C2779134260 @default.
• W4233236543 hasConceptScore W4233236543C2781228260 @default.
• W4233236543 hasConceptScore W4233236543C535046627 @default.
• W4233236543 hasConceptScore W4233236543C71924100 @default.
• W4233236543 hasLocation W42332365431 @default.
• W4233236543 hasLocation W42332365432 @default.
• W4233236543 hasLocation W42332365433 @default.
• W4233236543 hasLocation W42332365434 @default.
• W4233236543 hasLocation W42332365435 @default.
• W4233236543 hasOpenAccess W4233236543 @default.
• W4233236543 hasPrimaryLocation W42332365431 @default.
• W4233236543 hasRelatedWork W1965604728 @default.
• W4233236543 hasRelatedWork W2017587608 @default.
• W4233236543 hasRelatedWork W2056697517 @default.
• W4233236543 hasRelatedWork W3159250744 @default.
• W4233236543 hasRelatedWork W3211941980 @default.
• W4233236543 hasRelatedWork W4206755077 @default.
• W4233236543 hasRelatedWork W4256514411 @default.
• W4233236543 hasRelatedWork W4292236216 @default.
• W4233236543 hasRelatedWork W4317597626 @default.
• W4233236543 hasRelatedWork W2083697902 @default.
• W4233236543 isParatext "false" @default.
• W4233236543 isRetracted "false" @default.
• W4233236543 workType "article" @default.